BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares saw strong trading volume on Friday . 2,270,491 shares were traded during mid-day trading, an increase of 2% from the previous session’s volume of 2,223,138 shares.The stock last traded at $91.66 and had previously closed at $88.16.

A number of equities research analysts recently commented on the stock. Piper Jaffray Cos. reissued a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, April 20th. Oppenheimer Holdings Inc. reissued a “hold” rating and issued a $99.00 price objective on shares of BioMarin Pharmaceutical in a research note on Wednesday, June 1st. Leerink Swann restated a “buy” rating on shares of BioMarin Pharmaceutical in a report on Friday, June 10th. Wedbush restated a “neutral” rating and issued a $108.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday, April 19th. Finally, Cowen and Company restated a “buy” rating on shares of BioMarin Pharmaceutical in a report on Sunday, April 17th. Three research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $123.82.

The company’s market capitalization is $14.85 billion. The firm has a 50 day moving average price of $84.02 and a 200-day moving average price of $84.40.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, April 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.32. The firm had revenue of $236.70 million for the quarter, compared to analyst estimates of $240.21 million. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.43) earnings per share. On average, analysts expect that BioMarin Pharmaceutical Inc. will post ($3.02) EPS for the current fiscal year.

In other news, CFO Daniel K. Spiegelman sold 3,769 shares of BioMarin Pharmaceutical stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $87.07, for a total transaction of $328,166.83. Following the completion of the sale, the chief financial officer now directly owns 58,644 shares in the company, valued at approximately $5,106,133.08. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Daniel K. Spiegelman sold 20,841 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $89.88, for a total value of $1,873,189.08. Following the sale, the chief financial officer now owns 71,235 shares of the company’s stock, valued at $6,402,601.80. The disclosure for this sale can be found here.

Other large investors have recently made changes to their positions in the company. Jennison Associates raised its stake in shares of BioMarin Pharmaceutical by 25.0% in the third quarter. Jennison Associates now owns 150,000 shares of the company’s stock valued at $15,798,000 after buying an additional 30,000 shares in the last quarter. ING Groep raised its stake in shares of BioMarin Pharmaceutical by 524.1% in the third quarter. ING Groep now owns 15,460 shares of the company’s stock valued at $1,628,000 after buying an additional 12,983 shares in the last quarter. TD Asset Management Inc. raised its stake in shares of BioMarin Pharmaceutical by 0.3% in the fourth quarter. TD Asset Management Inc. now owns 105,383 shares of the company’s stock valued at $11,040,000 after buying an additional 310 shares in the last quarter. New York State Common Retirement Fund raised its stake in shares of BioMarin Pharmaceutical by 1.2% in the fourth quarter. New York State Common Retirement Fund now owns 432,300 shares of the company’s stock valued at $45,288,000 after buying an additional 5,100 shares in the last quarter. Finally, CAM Group Holding A S raised its stake in shares of BioMarin Pharmaceutical by 73.6% in the fourth quarter. CAM Group Holding A S now owns 127,575 shares of the company’s stock valued at $13,365,000 after buying an additional 54,100 shares in the last quarter.

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.